ATE553090T1 - Cathepsincysteinproteasehemmer - Google Patents

Cathepsincysteinproteasehemmer

Info

Publication number
ATE553090T1
ATE553090T1 AT06752874T AT06752874T ATE553090T1 AT E553090 T1 ATE553090 T1 AT E553090T1 AT 06752874 T AT06752874 T AT 06752874T AT 06752874 T AT06752874 T AT 06752874T AT E553090 T1 ATE553090 T1 AT E553090T1
Authority
AT
Austria
Prior art keywords
protease inhibitors
cathepsincystone
compounds
inhibitors
cathepsins
Prior art date
Application number
AT06752874T
Other languages
English (en)
Inventor
Cameron Black
Sheldon Crane
Renata Oballa
Joel Robichaud
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Application granted granted Critical
Publication of ATE553090T1 publication Critical patent/ATE553090T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06752874T 2005-07-06 2006-07-05 Cathepsincysteinproteasehemmer ATE553090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69697005P 2005-07-06 2005-07-06
PCT/CA2006/001104 WO2007003056A1 (en) 2005-07-06 2006-07-05 Cathepsin cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
ATE553090T1 true ATE553090T1 (de) 2012-04-15

Family

ID=37604075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06752874T ATE553090T1 (de) 2005-07-06 2006-07-05 Cathepsincysteinproteasehemmer

Country Status (8)

Country Link
US (1) US7928091B2 (de)
EP (1) EP1902031B1 (de)
JP (1) JP5122447B2 (de)
CN (2) CN103172568A (de)
AT (1) ATE553090T1 (de)
AU (1) AU2006265735B2 (de)
CA (1) CA2614070C (de)
WO (1) WO2007003056A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722734B2 (en) 2005-03-02 2014-05-13 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin K
BR112013015774A2 (pt) * 2010-12-01 2018-05-22 Nissan Chemical Industries Ltd compostos de pirazol tendo efeito terapêutico sobre mieloma múltiplo.
TWI523844B (zh) * 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
US9943522B2 (en) 2011-05-16 2018-04-17 Bayer Intellectual Property Gmbh Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
WO2013148202A1 (en) * 2012-03-29 2013-10-03 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Novel compositions and methods for preventing or treating cancer metastasis
EP2867227B1 (de) 2012-06-28 2018-11-21 Novartis AG Modulatoren des komplementweges und verwendungen davon
JP6454335B2 (ja) * 2013-10-08 2019-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． カテプシンシステインプロテアーゼ阻害剤
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015120580A1 (en) * 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015165374A1 (en) * 2014-04-29 2015-11-05 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase i
CN106960233A (zh) * 2017-03-20 2017-07-18 广州市度信息技术有限公司 基于rfid的物品位置异常监控方法及装置
CN113332420B (zh) * 2021-06-30 2023-07-28 蚌埠医学院 日本血吸虫半胱氨酸蛋白酶抑制剂在动脉粥样硬化方面的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525036B2 (en) 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
US6462076B2 (en) * 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
CA2466115A1 (en) 2001-11-13 2003-05-22 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Cyanoalkylamino derivatives as protease inhibitors
AU2004242865A1 (en) 2003-06-02 2004-12-09 F. Hoffmann-La Roche Ag Benzamide nitrile derivatives
US7405229B2 (en) * 2003-06-30 2008-07-29 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors

Also Published As

Publication number Publication date
US7928091B2 (en) 2011-04-19
CA2614070A1 (en) 2007-01-11
US20090093444A1 (en) 2009-04-09
EP1902031A1 (de) 2008-03-26
JP2009500300A (ja) 2009-01-08
CN101218207A (zh) 2008-07-09
CA2614070C (en) 2014-03-25
AU2006265735A1 (en) 2007-01-11
AU2006265735B2 (en) 2011-08-04
EP1902031B1 (de) 2012-04-11
EP1902031A4 (de) 2009-09-16
WO2007003056A1 (en) 2007-01-11
JP5122447B2 (ja) 2013-01-16
CN103172568A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
ATE395911T1 (de) Cathepsin-cystein-protease-hemmer
TW200631576A (en) Cathepsin cysteine protease inhibitors
ATE553090T1 (de) Cathepsincysteinproteasehemmer
ATE409482T1 (de) Cathepsincystein-proteasehemmer
NO20061627L (no) Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
NO20075370L (no) Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
NO20080661L (no) Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
WO2002070517A3 (en) Cathepsin cysteine protease inhibitors
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction
MY139221A (en) Cathepsin cysteine protease inhibitors
DOP2005000240A (es) Inhibidores de catepsina cisteina proteasas
UA95930C2 (uk) Інгібітори цистеїнпротеаз, фармацевтична композиція, яка їх містить, та їх терапевтичне застосування